ECTRIMS 2021 | Using artificial intelligence in MS clinical trials
Carmen Tur, MD, PhD, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain, outlines the potential applications of artificial intelligence (AI) in multiple sclerosis (MS) clinical trials. These include patient selection, enabling the identification of patients most likely to benefit from a given treatment, and novel outcome measure discovery. The use of AI is in its infancy in MS and while its potential to improve trial conduction and outcomes is apparent, much more research is needed. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.
Disclosures
Carmen Tur is currently being funded by a Junior Leader La Caixa Fellowship (fellowship code is LCF/BQ/PI20/11760008), awarded by “la Caixa” Foundation (ID 100010434). She has also received the 2021 Merck’s Award for the Investigation in MS, awarded by Fundación Merck Salud (Spain). In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society. She has also received honoraria from Roche and Novartis and is a steering committee member of the O’HAND trial and of the Consensus group on Follow-on DMTs.
